Creutzfeldt-Jakob Disease

Prion Protein Misfolding and Propagation

• Normal cellular prion protein (PrP^C) undergoes pathologic conformational change to disease-associated isoform (PrP^Sc)
• PrP^Sc adopts predominantly β-sheet structure (compared to α-helix in PrP^C), rendering it protease-resistant and prone to self-templating aggregation
• Misfolded prions act as infectious agents capable of inducing conformational change in native PrP^C molecules, establishing autocatalytic chain reaction
• Prion accumulation occurs selectively in neural tissue due to high constitutive PrP^C expression in neurons and glia

Neurodegeneration and Spongiform Changes

• Accumulation of PrP^Sc triggers neuronal dysfunction through multiple mechanisms: oxidative stress, disruption of synaptic transmission, impaired protein clearance, and activation of pro-apoptotic pathways
• Spongiform pathology (status spongiosus) develops with formation of microscopic vacuoles in gray matter, representing neuronal loss and gliosis without significant inflammation
• Loss of cortical neurons correlates directly with cognitive decline and motor deterioration

Genetic Determinants of Disease Phenotype

• PRNP gene polymorphism at codon 129 (methionine vs. valine) critically influences disease phenotype, incubation period, and clinical presentation
• Homozygosity at codon 129 (MM or VV) confers increased susceptibility and faster disease progression compared to heterozygous (MV) genotype
• Specific pathogenic mutations in PRNP (e.g., E200K, D178N, P102L) segregate with familial CJD and determine clinical subtype

Sporadic CJD (85% of cases)

• No identified epidemiologic risk factor or family history; mechanism of initial PrP^Sc generation remains unclear but may involve spontaneous protein misfolding or somatic mutations in PRNP
• Increased age is primary risk factor (median age 60–65 years); rare in patients <30 years

Familial/Genetic CJD (10–15% of cases)

• Autosomal dominant inheritance pattern with variable penetrance; caused by pathogenic germline mutations in PRNP gene
• Common mutations include E200K (Eastern European Jewish ancestry), D178N, P102L, and octapeptide repeat expansions
• Molecular subtyping based on PRNP mutation, codon 129 genotype, and PrP^Sc type (Type 1 vs. Type 2) predicts clinical phenotype

Iatrogenic CJD (2–3% of cases)

• Contaminated neurosurgical instruments inadequately sterilized despite standard protocols
• Cadaveric dura mater grafts (discontinued in most countries)
• Contaminated human growth hormone derived from cadaveric pituitaries (historical; now recombinant)
• Corneal transplants from CJD donors (extremely rare)
• Infected blood transfusions (vCJD variant; see below)

Variant CJD (vCJD) – Bovine Spongiform Encephalopathy (BSE) Exposure

• Consumption of BSE-contaminated beef products; documented transmission via food chain in UK outbreak (1990s–2000s)
• Predominantly affects younger patients (median age 28 years); clinically and pathologically distinct from sporadic CJD
• Rare in modern era due to enhanced food safety regulations; case fatality rate >99%

Other Risk Factors

• Occupational exposure (minimal risk for healthcare workers with standard precautions; tissue contact, especially CNS tissue, poses greatest risk)
• Homozygosity at PRNP codon 129 increases susceptibility to both sporadic and acquired forms

Cardinal Early Symptoms (often nonspecific)

• Cognitive decline (most common initial manifestation): progressive dementia with impaired memory, judgment, and concentration; rapid progression distinguishes CJD from other dementias
• Behavioral changes: personality alteration, depression, anxiety, or apathy often precede cognitive symptoms
• Sleep disturbances: insomnia, hypersomnia, or disrupted sleep-wake cycle frequently early and prominent feature

Neurologic Manifestations (progressive over weeks to months)

• Myoclonus: brief, involuntary jerks typically stimulus-sensitive or spontaneous; present in ~90% of sporadic CJD cases; may involve limbs or trunk
• Visual disturbances: blurred vision, visual field defects, cortical blindness, or Heidenhain variant (prominent early visual symptoms with occipital predominance on pathology)
• Cerebellar signs: ataxia, dysarthria, nystagmus reflecting cerebellar degeneration
• Pyramidal/extrapyramidal signs: spasticity, rigidity, bradykinesia, dystonia; progress to akinetic mutism and decorticate posturing in terminal stages
• Seizures: focal or generalized; occur in 10–15% of cases; may signal transition to severe disability

Consciousness and Motor Function Deterioration

• Progressive loss of consciousness progressing to vegetative state
• Akinetic mutism: patient appears awake but unresponsive to commands with minimal spontaneous activity
• Ultimately progresses to complete unresponsiveness requiring full supportive care

Clinical Subtypes (based on predominant symptoms)

• Classic (typical) CJD: cognitive decline with myoclonus and ataxia
• Heidenhain variant: prominent early visual symptoms with occipital predominance
• Cerebellar (ataxic) variant: prominent ataxia with relative preservation of cognition early
• Amyotropic variant: prominent motor neuron degeneration mimicking ALS
• Parkinsonian variant: rigidity and bradykinesia predominate
• Thalamic (familial) CJD: associated with D178N mutation; insomnia, autonomic symptoms, and ataxia prominent; slower progression (8–10 years)

Variant CJD (distinct phenotype)

• Prominent psychiatric symptoms (depression, anxiety, personality change) preceding neurologic manifestations by months
• Sensory symptoms: paresthesias, pain, dysesthesia
• Later onset of cognitive decline and myoclonus compared to sporadic CJD
• Pulvinar sign on MRI (selective pulvinar hyperintensity) pathognomonic finding

Clinical Diagnostic Criteria (probable CJD)

• Myoclonus (stimulus-sensitive preferred)
• Visual disturbances
• Pyramidal/extrapyramidal signs
• Cerebellar signs

MRI Neuroimaging Findings (diagnostic sensitivity varies by subtype; 60–90%)

• Diffusion-weighted imaging (DWI) hyperintensities: hallmark finding in cortical gray matter or basal ganglia reflecting restricted water diffusion from neuronal loss
• Fluid-attenuated inversion recovery (FLAIR) hyperintensities: increased T2/FLAIR signal in cortex and/or basal ganglia
• "Pulvinar sign": selective hyperintensity of posterior thalamic nuclei (pulvinar) on DWI/FLAIR; specific for variant CJD
• "Hockey stick sign": combination of pulvinar and medial thalamic hyperintensity
• Cortical ribboning: linear gray matter hyperintensity along cortical surface
• Basal ganglia hyperintensity: particularly putamen and caudate involvement
• Cerebellar atrophy in ataxic variants

Electroencephalography (EEG)

• Periodic sharp wave complexes (PSWCs): characteristic 1–2 Hz biphasic or triphasic waves appearing synchronously or generalized; highly specific (90%) but present in only 60% of cases
• Background slowing with progressive deterioration to delta activity and eventually electro-silence in terminal stages
• Absence of epileptiform activity helps exclude seizure disorders in differential diagnosis

Cerebrospinal Fluid (CSF) Analysis

• 14-3-3 protein: elevated in ~80% of sporadic CJD; most sensitive non-specific biomarker; high specificity when markedly elevated
• Tau protein (phosphorylated and total): markedly elevated in CJD (median ~1200 pg/mL); may be more specific than 14-3-3
• Real-time quaking-induced conversion (RT-QuIC) assay: newer amplification assay detecting misfolded prion protein with >90% sensitivity and specificity; increasingly available in specialized laboratories
• Protein 14-3-3 and RT-QuIC combination: CSF RT-QuIC positive in 92% of sporadic CJD; highest diagnostic accuracy
• Routine CSF parameters: normal protein, glucose, and cell counts; absence of pleocytosis helps exclude infectious meningitis/encephalitis
• Absence of oligoclonal bands: typically negative, distinguishing CJD from multiple sclerosis

Prion Protein Gene (PRNP) Sequencing

• Mandatory in all suspected CJD cases to identify pathogenic mutations associated with familial/genetic CJD
• Codon 129 polymorphism genotyping provides prognostic information (homozygosity MM or VV worse prognosis; MV better)
• Western blot analysis of CSF or tissue (rarely performed due to complexity and biosafety concerns) can detect protease-resistant PrP^Sc but impractical for clinical diagnosis

Brain Biopsy (rarely performed)

• Reserved for cases with atypical clinical presentation or diagnostic uncertainty
• Demonstrates spongiform pathology (vacuolation), neuronal loss, and gliosis with PrP^Sc immunostaining
• High biosafety risk; requires specialized handling; generally not recommended for diagnosis given less-invasive alternatives available
• Useful in excluding other treatable pathology in select cases

Diagnostic Algorithm Summary

1. 1.High clinical suspicion: rapidly progressive dementia with myoclonus/visual symptoms/cerebellar signs
2. 2.First-line: MRI (DWI/FLAIR) and EEG
3. 3.Confirmatory: CSF 14-3-3, tau, and RT-QuIC (if available)
4. 4.Genetic testing: PRNP sequencing in all cases
5. 5.PrP^Sc detection: RT-QuIC or Western blot if diagnostic uncertainty persists

Supportive Care (only evidence-based intervention)

• Symptomatic management remains cornerstone; no disease-modifying therapy proven effective
• Seizure prophylaxis with levetiracetam (500 mg PO BID-TID) or valproic acid if seizures develop; phenytoin avoided (induces metabolism of other medications)
• Myoclonus management: clonazepam (0.5–2 mg PO BID-QID) most effective; levetiracetam alternative; opioids (morphine, fentanyl) for severe cases
• Sleep hygiene optimization; melatonin or low-dose benzodiazepines (lorazepam) for insomnia

Investigational Therapies (limited evidence; not standard of care)

• Quinacrine (100–300 mg PO daily): showed minimal benefit in controlled trials; accumulated some anecdotal response but not recommended routinely
• Flupirtine (off-market in many countries due to safety): NMDA channel blocker; marginal efficacy with liver toxicity concerns
• Immunotherapy: limited case reports with intravenous immunoglobulin (IVIG) or plasma exchange; insufficient evidence
• Anti-prion monoclonal antibodies: preclinical phase; not yet in human trials with clinical endpoints
• Misfolded protein clearance enhancers (e.g., ampicillin, doxycycline combinations): anecdotal case reports only
• Participation in clinical trials strongly encouraged; disease progression typically too rapid for agents to demonstrate benefit

Non-Pharmacological Measures

• Infection control precautions: standard precautions sufficient for most patient care; increased precautions for handling CNS tissue
• Instruments/equipment contact with CNS tissue require specialized sterilization (autoclaving at 121°C for ≥18 minutes or sodium hypochlorite soaking)
• Palliative care consultation early; emphasis on comfort measures and end-of-life planning given uniformly fatal prognosis
• Speech therapy for dysarthria; physical/occupational therapy for functional decline
• Nutritional support: nasogastric or percutaneous endoscopic gastrostomy (PEG) in select cases; generally avoided given poor prognosis and patient wishes
• Psychosocial support for family members confronting rapid deterioration

Monitoring and Reassessment

• Serial neurologic examinations document disease progression
• Repeat imaging (MRI) not routinely required after initial diagnostic confirmation
• EEG not required for follow-up; clinical progression sufficient for monitoring
• Frequent communication with family regarding prognosis, disease trajectory, and goals of care

Aspiration and Respiratory Compromise

• Aspiration pneumonia: frequent terminal complication due to progressive dysphagia and loss of protective airway reflexes
• Managed supportively with antibiotics if consistent with goals of care; recurrent aspiration often signals terminal decline
• Respiratory failure: may result from central hypoventilation, myoclonic movements interfering with respiration, or aspiration
• Mechanical ventilation rarely pursued given uniformly fatal prognosis and patient preferences; generally considered non-beneficial

Status Epilepticus and Severe Myoclonus

• Uncontrolled seizures or myoclonus despite maximal medical therapy occur in 10–15% of cases
• Myoclonic status epilepticus: severe, continuous myoclonic jerks refractory to standard anticonvulsants
• Managed with high-dose benzodiazepines (lorazepam, midazolam infusions) and concurrent antiepileptic agents
• Often signals terminal phase with poor prognosis for meaningful recovery

Severe Behavioral Disturbance

• Behavioral disinhibition, aggression, or psychosis: occur as cognitive decline progresses
• Managed with atypical antipsychotics (risperidone 0.5–2 mg BID, quetiapine 25–100 mg TID); avoid typical neuroleptics (increase myoclonus/rigidity)
• Safety measures implemented if patient poses harm to self/others

Autonomic Dysfunction

• Dysregulation of blood pressure, heart rate, temperature: progressive autonomic failure in later stages
• May manifest as sustained hypertension, labile blood pressure, cardiac arrhythmias, or hypothermia
• Rarely directly managed; reflected in overall supportive care

Akinetic Mutism and Vegetative State (terminal complication)

• Patient becomes unresponsive, unable to communicate, requiring total nursing care
• Indistinguishable from vegetative state or minimally conscious state; recovery essentially never occurs
• Families require extensive counseling regarding realities of care burden and quality of life

Transmission Risk (Healthcare-Associated)

• Occupational exposure: risk primarily to personnel handling CNS tissue, neurosurgical instruments, or contaminated materials
• Documented transmission via contaminated surgical instruments very rare (<1 in 1 million procedures) with standard sterilization protocols
• Enhanced precautions for tissue handling and instrument sterilization essential; no documented transmission to healthcare workers with proper infection control measures

Natural History and Survival

• Median survival: 12–14 months from symptom onset in sporadic CJD (range

• The stem triad: dementia progressing over weeks to months (not years) + myoclonus, classically startle- or stimulus-sensitive + cerebellar/visual signs. Any dementia that outpaces Alzheimer disease by an order of magnitude should trigger prion disease on the differential.
• Single best next step: MRI brain with DWI (with FLAIR/ADC correlation). Cortical ribboning and caudate/putamen hyperintensity with restricted diffusion is the highest-yield image; DWI outperforms both EEG and 14-3-3 and is embedded in the CDC surveillance diagnostic criteria for probable sporadic CJD.
• Best confirmatory test short of autopsy: CSF RT-QuIC, which amplifies misfolded PrP directly and is now part of the CDC criteria. In the U.S. it is run by the National Prion Disease Pathology Surveillance Center, to which suspected cases should be referred.
• Common distractor — 14-3-3: a nonspecific marker of rapid neuronal injury, also elevated in stroke, herpes encephalitis, and status epilepticus. Do not pick it over RT-QuIC or DWI as the most specific test.
• The association examiners love: codon 129 methionine/valine polymorphism of PRNP; homozygosity increases susceptibility. Also test-favored: E200K (familial CJD, Libyan/Eastern European Jewish ancestry) and D178N with 129M (fatal familial insomnia).
• vCJD versus sporadic: young patient, psychiatric/sensory prodrome, bovine exposure, and the pulvinar sign (or hockey stick sign) on MRI — not a feature of sporadic disease.
• Rule out the treatable mimics first: autoimmune/paraneoplastic encephalitis (anti-NMDAR, LGI1, anti-Hu), Hashimoto encephalopathy, neurosyphilis, B12 deficiency, and CNS lymphoma. The 2016 Graus criteria for autoimmune encephalitis exist precisely because these are steroid- or immunotherapy-responsive; CJD is not.
• Infection control detail: prions resist formalin, alcohol, and routine autoclaving. Standard precautions suffice for routine care; CNS-contacting instruments require extended autoclaving plus sodium hydroxide or hypochlorite. Patients are permanently excluded from blood, organ, and tissue donation.
• Prognosis: uniformly fatal, no disease-modifying therapy — early palliative care is the correct management answer.